Publications by authors named "Savoye G"
Article Synopsis
- The incidence of inflammatory bowel disease (IBD) in Northern France was studied over a 30-year period, revealing 22,879 new cases, with Crohn's disease (CD) and ulcerative colitis (UC) making up the majority.
- The incidence rates for both CD and UC increased significantly over the years, particularly in children and young adults, indicating a rising trend in these demographics.
- The findings suggest ongoing environmental factors contributing to the increasing prevalence of IBD, especially among women with UC, with projections indicating that nearly 0.6% of the population will have IBD by 2030.
Article Synopsis
- Patients with inflammatory bowel disease (IBD), specifically children with Crohn's disease (CD) and ulcerative colitis (UC), have a higher risk of thromboembolic events (TE), but more information is needed regarding the incidence and risk factors for better preventative care.
- The study followed 1,344 pediatric patients from 1988 to 2013, finding very few instances of arterial (ATE) and venous thromboembolic events (VTE) during the follow-up period, with VTE being more frequent in specific circumstances.
- Overall, while the risk of TE in this population is low, it was significantly linked to periods of active disease, post-surgery conditions, and hospitalization, while treatment with
Article Synopsis
- A study was conducted with 941 IBD patients to assess their satisfaction with different adalimumab preparations, including biosimilars and the original brand, Humira.
- The average satisfaction rating was 8.5 out of 10, with the highest satisfaction observed for Humira and its biosimilars like Hulio and Amgevita, where scores were notably above 8.5.
- Injection site reactions were reported by 31.8% of patients, and a portion of those previously treated with another adalimumab had discontinued due to side effects; overall, patient satisfaction remained high despite these issues.
Background: Acute gastrointestinal bleeding (AGIB) is common in older patients but the use of iron in this context remains understudied.
Aims: This study aimed to evaluate prospectively the efficacy of ferric carboxymaltose to treat anaemia in older patients after AGIB.
Methods: This randomised double-blinded placebo-controlled clinical trial was conducted in 10 French centres.
Purpose: Perianal fistulae are disabling complications of Crohn's Disease. Magnetic resonance imaging features could predict treatment response. This study aimed to determine which magnetic resonance imaging features were predictive of long-term clinical outcome in real life.
View Article and Find Full Text PDFCrohn's disease affects 2.5 million people in Europe (more than 100,000 people in France) and often occurs between the ages of 15 and 30, a period marked by self-construction. However, few studies have focused on the experience of the diagnosis during this sensitive developmental stage.
View Article and Find Full Text PDFBackground: Inflammatory bowel disease [IBD] is associated with an increased risk of developing lymphoma. Although recent data have clarified the epidemiology of lymphoma in IBD patients, the clinical and pathological characteristics of lymphoma in IBD remain poorly known.
Methods: Patients with IBD and lymphoma were retrospectively identified in the framework of a national collaborative study including the Groupe d'Étude Thérapeutique des Affections Inflammatoires du Tube Digestif [GETAID] and the Lymphoma Study Association [LYSA].
Background: Psychometric validation of the Multidimensional Chronic Asthenia Scale (MCAS) was conducted in order to provide an effective tool for assessing the health-related quality of life of French-speaking patients with chronic asthenia (CA).
Methods: Items resulting from the initial formulation of the self-reported MCAS (along with other materials) were completed by French-speaking volunteers with inactive or active inflammatory bowel disease (IBD-I vs. IBD-A) or chronic fatigue syndrome (CFS).
Background: Although ulcerative proctitis [UP] can dramatically impair quality of life, treatment efficacy has been poorly investigated in UP as it was historically excluded from phase 2/3 randomised controlled trials in ulcerative colitis. Our aim was to assess the effectiveness and safety of tofacitinib for the treatment of UP.
Methods: We conducted a retrospective, multicentre study in 17 GETAID centres, including consecutive patients with UP treated with tofacitinib.
Prevalence of and Factors Associated With Extraintestinal Manifestations and Their Remission in Inflammatory Bowel Disease: The EXTRA-Intestinal Manifestation Prospective Study From the Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif.
Clin Transl Gastroenterol
December 2023
Introduction: Extraintestinal manifestations (EIMs) of inflammatory bowel disease (IBD) are challenging clinical situation. No prospective study assessed remission risk factors of EIMs. The aim of this study was to prospectively investigate the epidemiology, risk factors of EIM occurrence, and EIM remission in a large IBD cohort.
View Article and Find Full Text PDFCrohn's disease (CD) is an inflammatory bowel disease characterized by immune-mediated flares affecting any region of the intestine alternating with remission periods. In CD, the ileum is frequently affected and about one third of patients presents with a pure ileal type. Moreover, the ileal type of CD presents epidemiological specificities like a younger age at onset and often a strong link with smoking and genetic susceptibility genes.
View Article and Find Full Text PDFBackground: The identification of patients at high risk of a disabling disease course would be invaluable in guiding initial therapy in Crohn's disease (CD). Our objective was to evaluate a combination of clinical, serological, and genetic factors to predict complicated disease course in pediatric-onset CD.
Methods: Data for pediatric-onset CD patients, diagnosed before 17 years of age between 1988 and 2004 and followed more than 5 years, were extracted from the population-based EPIMAD registry.
Background: In recent years, an increasing prevalence of obesity in inflammatory bowel disease (IBD) has been observed. However, only a few studies have focused on the impact of overweight and obesity on IBD-related disability.
Aims: To identify the factors associated with obese and overweight patients with IBD, including IBD-related disability.
Introduction: We evaluated the impact of immunosuppressants (IS) and antitumor necrosis factor (TNF) introduction on long-term outcomes of ulcerative colitis (UC) in a large population-based pediatric-onset cohort.
Methods: All patients included in the EPIMAD registry with a diagnosis of UC made before the age of 17 years between 1988 and 2011 were followed up retrospectively until 2013. Medication exposure and disease outcomes were compared between 3 diagnostic periods: 1988 to 1993 (period [P] 1; pre-IS era), 1994 to 2000 (P2; pre-anti-TNF era), and 2001 to 2011 (P3; anti-TNF era).
Article Synopsis
- Anti-TNF agents, commonly used to treat inflammatory bowel disease in patients diagnosed before age 17, show varied long-term effectiveness, especially in pediatric cases.
- A study of 1,007 Crohn's disease patients and 337 ulcerative colitis patients revealed significant failure rates for first-line anti-TNF therapy, with risks higher in the first year and female patients having increased rates of loss of response and intolerance.
- Despite 13.5% experiencing adverse events leading to treatment cessation, there were no deaths or serious conditions like cancer reported during anti-TNF therapy.
Article Synopsis
- Anal ulcerations are common in pediatric patients with Crohn's disease, with 25.6% experiencing them at diagnosis, and the 5 and 10-year cumulative incidence being 38.4% and 44.0%, respectively.
- Extraintestinal symptoms and locations of Crohn's disease in the upper digestive tract increase the risk of developing anal ulcerations, while ileal locations reduce that risk.
- A history of anal ulceration significantly raises the likelihood of developing fistulizing perianal Crohn's disease, with 23.3% of patients experiencing this after several years of follow-up.
Article Synopsis
- Fatigue is a common issue in patients with inflammatory bowel disease (IBD), with 54.1% experiencing fatigue and 37.1% reporting severe fatigue.
- Patients with active IBD experience significantly higher levels of fatigue compared to those with inactive disease.
- Key factors affecting fatigue include age, gender, sick leave, physical pain, emotional well-being, and sleep quality, suggesting that a holistic treatment approach is essential for managing IBD-related fatigue.
Background And Aims: Paediatric-onset IBD [pIBD] is associated with an increased risk of cancer and mortality in adulthood. The aims of this study were to measure the incidence of cancer and mortality in patients with pIBD and identify factors associated with mortality and cancer.
Methods: All patients diagnosed with Crohn's disease [CD] or ulcerative colitis [UC] before the age of 17 years between 1988 and 2011 in the EPIMAD registry were retrospectively followed until 2013 for cancer and 2015 for mortality.
Background: Intestinal fibrosis is a common complication in inflammatory bowel disease (IBD) patients without specific treatment. Aryl hydrocarbon receptor (AhR) activation is associated with better outcomes in intestinal inflammation. Development of novel therapies targeting fibrogenic pathways is required and we aimed to screen dietary AhR ligands for their anti-fibrotic properties in TGF-β1-stimulated human colonic fibroblast cells.
View Article and Find Full Text PDFBackground: Use of a combination of targeted therapies (COMBIO) in patients with refractory/overlapping immune-mediated inflammatory diseases (IMIDs) has increased, but reported data remain scarce. We aimed to assess effectiveness and safety of COMBIO in patients with IMIDs.
Methods: We conducted a French ambispective multicenter cohort study from September 2020 to May 2021, including adults' patients with 1 or 2 IMIDs and treated at least 3-month with COMBIO.
Introduction: There are currently no comparative data on the efficacy and safety of vedolizumab and ustekinumab in ulcerative colitis (UC) after anti-TNF therapy fails.
Methods: We retrieved the full datasets of two observational, multicentre, retrospective studies of patients with UC for whom anti-TNF therapy failed and the patients were then treated with either vedolizumab or ustekinumab. The outcomes included steroid-free clinical remission, clinical remission, treatment persistence, colectomy, hospitalization, and serious and infectious adverse events.
Introduction: Knowledge about the cancer risk when initiating a biologic in inflammatory bowel disease [IBD] patients with prior malignancy remains scarce, especially for vedolizumab. Our aim was to evaluate the rate of incident cancer in a cohort of IBD patients with prior non-digestive malignancy, according to the subsequent treatment given.
Methods: A multicentre retrospective study included consecutive IBD patients with prior non-digestive malignancy.
Background: Iron deficiency (ID) is a frequent condition in patients with inflammatory bowel disease (IBD).
Aim: Our aim was to investigate the prevalence of ID in patients with IBD.
Methods: This was a prospective multicenter cross-sectional study conducted in 21 gastroenterology departments in France between January and March 2020.
Intestinal fibrosis is a common complication in inflammatory bowel disease (IBD) without specific treatment. As macrophages are the key actors in inflammatory responses and the wound healing process, they have been extensively studied in chronic diseases these past decades. By their exceptional ability to integrate diverse stimuli in their surrounding environment, macrophages display a multitude of phenotypes to underpin a broad spectrum of functions, from the initiation to the resolution of inflammation following injury.
View Article and Find Full Text PDFBackground & Aims: We evaluated the impact of immunosuppressants (IS) and anti-tumor necrosis factor (TNF) introduction on Crohn's disease (CD) long-term outcomes in a large population-based, pediatric-onset cohort.
Methods: All patients included in the EPIMAD registry with a diagnosis of CD occurring when they were younger than age 17 years and between 1988 and 2011 were followed up retrospectively until 2013. Three diagnostic periods were defined: 1988 to 1993 (period [P]1; pre-IS era), 1994 to 2000 (P2; pre-anti-TNF era), and 2001 to 2011 (P3; anti-TNF era).